CDP323

CDP323 is a small-molecule prodrug antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to α4-integrins. It was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis. [Davenport RJ, Munday JR. "Alpha4-integrin antagonism - an effective approach for the treatment of inflammatory diseases?" Drug Discov Today 2007;12:569-76. PMID 17631252]

In October 2006, UCB S.A. and Biogen Idec announced a collaboration to jointly develop and commercialize CDP323 for the treatment of multiple sclerosis and other potential indications. [ [http://hugin.info/133973/R/1079005/186265.pdf Press Release UCB S.A.] 2-Oct-2006; accessed 11-Sep-2007]

Mechanism of action

The mechanism of action of CDP323 is believed to rely on preventing immune cells to migrate from blood vessels through the vessel walls to reach various inflamed tissues, including the brain. This mechanism is thought to prevent overshooting immune reactions and subsequent tissue damage as seen during uncontrolled immune cell migration as in multiple sclerosis. CDP323 has the same mechanism of action as the monoclonal antibody natalizumab.

Results in animal models

CDP323 was investigated in chronic experimental autoimmune encephalomyelitis (EAE) in mice. The drug was effective when given prophylactically (i.e., before the disease was induced in mice) and when given therapeutically (i.e., after outbreak of the disease) and reduced the disease severity significantly. [ [http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=13753&XNSPRACHE_ID=2&XNKONGRESS_ID=22&XNMASKEN_ID=900 Watt G, Gauden V, McNeil K et al. "Effect of CDP323, a small molecule VLA-4 antagonist, on chronic experimental allergic encephalomyelitis in C57Bl/6 mice".] ECTRIMS 2005; accessed 11-Sep-2007]

Clinical development

The safety, tolerability, and pharmacokinetic profile of CDP323 have been evaluated in 75 female and male healthy volunteers in three separate Phase 1 studies. CDP323 was well tolerated at oral doses up to 1000 mg given twice daily for 7 consecutive days with an adverse event profile comparable to that observed with placebo. There was no gender effect. The oral administration resulted in inhibition of VCAM-1 binding which could be maintained throughout a 12 or 24 hour dose interval at well tolerated doses [ [http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=31558&XNSPRACHE_ID=2&XNKONGRESS_ID=39&XNMASKEN_ID=900 Baker M, Shock A, Parton T et al. "Pharmacokinetic and pharmacodynamic properties of the VLA-4 inhibitor CDP323".] ECTRIMS 2006; accessed 11-Sep-2007]

A Phase 2 study commenced in June 2007 in Europe and in the US. The study intends to enroll over 200 patients with relapsing MS who have failed earlier treatment with an interferon-beta and will compare two doses of the drug to placebo over a period of six months. The results are expected by the end of 2008. [ [http://hugin.info/133973/R/1135424/212873.pdf Press Release UCB S.A.] 26-Jun-2007; accessed 11-Sep-2007] , [ [http://www.clinicaltrial.gov/ct/show/NCT00484536?order=1 Clinicaltrial.gov Entry] ; accessed 11-Sep-2007]

References

External links

* [http://clinicaltrials.gov/search/intervention=CDP323 Listings in the US NIH trial registry]